Investigating the Relationship Between Interleukin-6 Serum Levels and Outcome in Acute Ischemic CVA

Overview

Journal Brain Behav

Specialty Psychology

Date 2020 Jun 26

PMID 32583980

Citations 5

Authors

Arash Mosarrezaii

Mohammad Reza Amiri-Nikpour

Hamid Reza Mehryar

Babak Choobi Anzali

Sarmad Nourooz-Zadeh

Shadi Babaei

Hedieh Farrokhi

Affiliations

Soon will be listed here.

Abstract

Introduction: Interleukin-6 (IL-6) is among the inflammatory mediators exhibiting elevated levels in ischemic stroke (IS) patients. The present study set out to evaluate the relationship between serum levels of interleukin-6 with long-term and at-hospital outcomes of acute ischemic stroke in patients hospitalized at Imam Khomeini Hospital, Urmia, Iran, from 2017 to 2018.

Method And Materials: This cross-sectional descriptive study enrolled 29 and 31 acute stroke patients for long-term and at-hospital observation, respectively. Evaluation of stroke severity was performed using the National Institute of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) on days 1, 5, and 90. Serum IL-6 level was measured via enzyme-linked immunosorbent assay (ELISA) on days one and five.

Results: In the present cohort study, the following population were enrolled: for long-term evaluation, 11 (38%) men and 18 (63%) women with a mean age of 64.5 ± 14.9 years, and for at-hospital evaluation: 11 (37.5%) men and 20 (64.5%) with a mean age of 65.25 ± 14.37 years. A significant positive correlation was observed between IL-6 levels with NIHSS and mRS scores of the patients from time of admission until the end of the follow-up period (long-term: p < .001; at-hospital: 0.022).

Conclusion: The evidence from the present study suggests that IL-6 contributes to the determination of the severity of ischemic strokes and may be useful in predicting prognosis. However, larger scale studies are required to further establish these finds.

Citing Articles

Biomarkers and the outcomes of ischemic stroke.

Huang Y, Wang Z, Huang Z, Liu Z Front Mol Neurosci. 2023; 16:1171101.

PMID: 37342100 PMC: 10277488. DOI: 10.3389/fnmol.2023.1171101.

Biomarkers for prognostic functional recovery poststroke: A narrative review.

Jiaqi Zhang J, Sanchez Vidana D, Chan J, Hui E, Lau K, Wang X Front Cell Dev Biol. 2023; 10:1062807.

PMID: 36699006 PMC: 9868572. DOI: 10.3389/fcell.2022.1062807.

Jak2 Inhibitor AG490 Improved Poststroke Central and Peripheral Inflammation and Metabolic Abnormalities in a Rat Model of Ischemic Stroke.

Wang Y, Lin S, Chang C, Wu C, Chen W, Liao S Antioxidants (Basel). 2021; 10(12).

PMID: 34943061 PMC: 8750281. DOI: 10.3390/antiox10121958.

Neopterin and kynurenic acid as predictors of stroke recurrence and mortality: a multicentre prospective cohort study on biomarkers of inflammation measured three months after ischemic stroke.

Alme K, Ulvik A, Askim T, Assmus J, Mollnes T, Naik M BMC Neurol. 2021; 21(1):476.

PMID: 34879833 PMC: 8653541. DOI: 10.1186/s12883-021-02498-w.

Investigating the relationship between interleukin-6 serum levels and outcome in acute ischemic CVA.

Mosarrezaii A, Amiri-Nikpour M, Mehryar H, Anzali B, Nourooz-Zadeh S, Babaei S Brain Behav. 2020; 10(8):e01668.

PMID: 32583980 PMC: 7428482. DOI: 10.1002/brb3.1668.

References

Fahmi R, Elsaid A . Infarction Size, Interleukin-6, and Their Interaction Are Predictors of Short-Term Stroke Outcome in Young Egyptian Adults. J Stroke Cerebrovasc Dis. 2016; 25(10):2475-81. DOI: 10.1016/j.jstrokecerebrovasdis.2016.06.021. View

Beamer N, Coull B, Clark W, Hazel J, Silberger J . Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37(6):800-5. DOI: 10.1002/ana.410370614. View

Bharosay A, Saxena K, Varma M, Bharosay V, Pandey A . Correlation between proinflammatory serum markers: high sensitivity C-reactive protein, interleukin-6 with disability score in acute ischemic stroke. Indian J Clin Biochem. 2012; 26(3):279-82. PMC: 3162955. DOI: 10.1007/s12291-011-0135-1. View

Mirzaei M, Truswell A, Arnett K, Page A, Taylor R, Leeder S . Cerebrovascular disease in 48 countries: secular trends in mortality 1950-2005. J Neurol Neurosurg Psychiatry. 2011; 83(2):138-45. DOI: 10.1136/jnnp-2011-300408. View

Dziedzic T, Slowik A, Szczudlik A . Interleukin-6 and stroke: cerebral ischemia versus nonspecific factors influencing interleukin-6. Stroke. 2003; 34(12):e229-30. DOI: 10.1161/01.STR.0000103350.88094.5B. View

Mosarrezaii A, Amiri-Nikpour M, Mehryar H, Anzali B, Nourooz-Zadeh S, Babaei S . Investigating the relationship between interleukin-6 serum levels and outcome in acute ischemic CVA. Brain Behav. 2020; 10(8):e01668. PMC: 7428482. DOI: 10.1002/brb3.1668. View

Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A . Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci. 1999; 162(2):185-8. DOI: 10.1016/s0022-510x(98)00319-0. View

Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M . Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994; 122(2):135-9. DOI: 10.1016/0022-510x(94)90289-5. View

Woiciechowsky C, Schoning B, Lanksch W, Volk H, Docke W . Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med (Berl). 2000; 77(11):769-80. DOI: 10.1007/s001099900051. View

10.

Monje M, Toda H, Palmer T . Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003; 302(5651):1760-5. DOI: 10.1126/science.1088417. View

11.

Meng C, Zhang J, Shi R, Zhang S, Yuan S . Inhibition of interleukin-6 abolishes the promoting effects of pair housing on post-stroke neurogenesis. Neuroscience. 2015; 307:160-70. DOI: 10.1016/j.neuroscience.2015.08.055. View

12.

Lakhan S, Kirchgessner A, Hofer M . Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009; 7:97. PMC: 2780998. DOI: 10.1186/1479-5876-7-97. View

13.

Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S . Acute ischemic stroke update. Pharmacotherapy. 2010; 30(5):493-514. DOI: 10.1592/phco.30.5.493. View

14.

Whiteley W, Chong W, Sengupta A, Sandercock P . Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009; 40(5):e380-9. DOI: 10.1161/STROKEAHA.108.528752. View

15.

Oto J, Suzue A, Inui D, Fukuta Y, Hosotsubo K, Torii M . Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth. 2008; 22(3):207-12. DOI: 10.1007/s00540-008-0639-x. View

16.

Rodriguez-Yanez M, Castillo J . Role of inflammatory markers in brain ischemia. Curr Opin Neurol. 2008; 21(3):353-7. DOI: 10.1097/WCO.0b013e3282ffafbf. View

17.

Cojocaru I, Cojocaru M, Tanasescu R, Iliescu I, Dumitrescu L, Silosi I . Expression of IL-6 activity in patients with acute ischemic stroke. Rom J Intern Med. 2010; 47(4):393-6. View

18.

Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr K, Aarseth J . IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005; 111(6):360-5. DOI: 10.1111/j.1600-0404.2005.00416.x. View

19.

Esenwa C, Elkind M . Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. 2016; 12(10):594-604. DOI: 10.1038/nrneurol.2016.125. View

20.

Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K . Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke. 1995; 26(4):676-80; discussion 681. DOI: 10.1161/01.str.26.4.676. View